The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Konverge 40 mg/5 mg film-coated tablets

40/5 mg/mg Film-coated tablet

PCO Manufacturing Ltd.PPA0465/313/001

Main Information

Trade NameKonverge 40 mg/5 mg film-coated tablets
Active SubstancesAmlodipine besylate
Olmesartan medoxomil
Strength40/5 mg/mg
Dosage FormFilm-coated tablet
Licence HolderPCO Manufacturing Ltd.
Licence NumberPPA0465/313/001

Group Information

ATC CodeC09DB Angiotensin II antagonists and calcium channel blockers
C09DB02 olmesartan medoxomil and amlodipine


Licence Issued02/08/2013
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0046-094-003
Interchangeable List DocumentPDF of Interchangeable List
« Back